RET-AREAL: a multi-center, real-world data analysis on the efficacy of pralsetinib in acquired RET fusion after resistance to EGFR/ALK-TKIs.
Tang X, Hu J, Guo R, Wang Y, Yao Y, Zeng L, Wang H, Shen H, Chen J, Huang W, Liu L, Su M, Yu Z, Mao W, Wang J, Tao H, Dong G, Cai C, Xie Y, Qu T, Zhang Y, Shen W, Cao J, Cai X, Kong W, Li X, Liang F.
Tang X, et al. Among authors: shen h.
Cancer Lett. 2025 Jan 10:217455. doi: 10.1016/j.canlet.2025.217455. Online ahead of print.
Cancer Lett. 2025.
PMID: 39800214